No Data
No Data
Guoyuan Securities: Each overseas business model has its own advantages and disadvantages. Pharmaceutical companies should choose according to their own size.
Leveraging external resources is currently the most mainstream mode for Chinese pharmaceutical companies to expand overseas, which is suitable for companies with limited resources and in need of international experience accumulation, but it also means that the company's voice will be weakened and the relative benefits of sharing will be limited.
Consun Pharma (1681.HK): The management's significant increase in shareholding boosts market confidence.
In the first half of 2024, under the market capital preference for value stocks, Consun Pharma, with its stable growth performance and continuous high-proportion dividend strategy over the years, has been bullish by many investors and analysts. The pre-right price cumulative increase is over 33%, and the price volatility is over 51%. The highest price is HKD 7.16, which obviously outperforms the Hang Seng Index and the Hong Kong stock pharmaceutical sector. Since mid-May, affected by the adjustment of the Hong Kong stock market and the exercise of subscription rights by the company's first and second largest shareholders, investors have misunderstood this operation as high-level reduction of shareholding by shareholders, leading to a slight retreat of Consun Pharma's stock price. Recently, Consun
Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).
Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.
Consun Pharma (01681.HK) received 1.473 million shareholding increase from Executive Director An Meng.
According to the latest equity disclosure information from the Hong Kong Stock Exchange, from July 3 to July 5, 2024, Consun Pharma (01681.HK) saw director An Meng (chairman) increase his shareholding by a total of 1.473 million shares, at an average price of HK$5.61-5.90 per share, involving approximately HK$8.6465 million. After the increase, An Meng's latest shareholding has reached 213,328,000 shares, and his shareholding ratio has increased from 25.09% to 25.26%.
Consun Pharma (01681.HK) Chairman An Meng spent HKD 8.6465 million on shareholding, increasing it to 25.26% and expressing confidence in the company's future development.
According to the latest equity disclosure information from the Stock Exchange of Hong Kong, Consun Pharma (01681.HK), as disclosed by the board of directors chairman, An Meng, has acquired an additional 0.123 million shares, 0.05 million shares, and 1.3 million shares respectively on July 3 to July 5 in the stock market at an average price of HKD 5.61, HKD 5.73, and HKD 5.9 per share. The total number of shares acquired is 1.473 million with a total amount of approximately HKD 8.6465 million. After the shareholding, An Meng's latest shareholding number is 0.213 billion shares, with the latest shareholding ratio of 25.26%. Market analysts believe that this shows his firm confidence in the company's future development prospects.
Hong Kong stock market concept tracking | Heavy policies supporting the development of innovative drugs are introduced! The industry is expected to enter the fast lane of development (with concept stocks).
On July 5th, the State Council's executive meeting discussed and deployed the work related to promoting high-quality development of the digital economy, and approved the Implementation Plan for Supporting the Development of Innovative Drugs throughout the Whole Chain.
No Data